Boston-based CereVasc designed eShunt for treating normal pressure hydrocephalus (NPH). This study evaluates the technology ...
Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback